890.00p+75.00 (+9.20%)01 Mar 2024, 17:15
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

4Basebio PLC Fundamentals

Company Name4Basebio PLCLast Updated2024-03-01
IndustryBiotechnologySectorHealthcare
Shares in Issue12.805 mMarket Cap£113.97 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.42EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio3.3879Cash Equity Ratio1.0431
Quick Ratio2.4380Current Ratio3.42
Price To Book Value33.4448ROCE0

4Basebio PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

4Basebio PLC Company Financials

Assets20222021
Tangible Assets£3.63 m£2.76 m
Intangible Assets£2.12 m£1.27 m
Investments00
Total Fixed Assets£5.79 m£4.06 m
Stocks£133,000.00£156,000.00
Debtors£54,000.00£46,000.00
Cash & Equivalents£4.35 m£9.59 m
Other Assets00
Total Assets£11.69 m£14.70 m
Liabilities20222021
Creditors within 1 year£1.52 m£1.52 m
Creditors after 1 year£3.05 m£1.48 m
Other Liabilities00
Total Liabilities£4.57 m£3.01 m
Net assets£7.12 m£11.70 m
Equity20222021
Called up share capital£11.13 m£11.13 m
Share Premium£706,000.00£706,000.00
Profit / Loss-£5.93 m-£3.64 m
Other Equity£7.12 m£11.70 m
Preference & Minorities00
Total Capital Employed£7.12 m£11.70 m
Ratios20222021
Debt Ratio£0.29£0.10
Debt-to-Equity£0.41£0.11
Assets / Equity3.38793.3879
Cash / Equity1.04311.0431
EPS-£0.42-£0.24
Cash Flow20222021
Cash from operating activities-£4.70 m-£2.74 m
Cashflow before financing-£3.46 m-£3.21 m
Increase in Cash-£5.40 m-£4.72 m
Income20222021
Turnover£268,000.00£338,000.00
Cost of sales£29,000.00£69,000.00
Gross Profit£239,000.00£269,000.00
Operating Profit-£5.84 m-£3.53 m
Pre-Tax profit-£5.93 m-£3.64 m

4Basebio PLC Company Background

SectorHealthcare
Activities4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.
Latest Interim Date21 Sep 2023
Latest Fiscal Year End Date11 May 2023

4Basebio PLC Directors

AppointedNamePosition
2021-02-12Mr. Timothy Paul McCarthyNon-Executive Director,Chairman
2022-05-12Dr. Joseph M. FernandezNon-Executive Director
2021-02-12Mr. Hansjorg PlaggemarsNon-Executive Director
2024-02-05Dr. Heikki Lanckriet, PhDExecutive Director,Chief Executive Officer
2024-02-05Mr. David John RothExecutive Director,Chief Financial Officer and Company Secretary

4Basebio PLC Contact Details

Company Name4basebio PLC
Address25 Norman Way, Over, Cambridge, CB24 5QE
Telephone+44 1223967943
Websitehttps://www.4basebio.com

4Basebio PLC Advisors